Tofacent is identified on this website as a product containing 5 mg of tofacitinib. Its manufacturer, dosage form and regulatory authorization require verification.
Tofacitinib is an oral Janus kinase inhibitor used for selected immune-mediated inflammatory conditions.
Current U.S. labeling includes selected patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, pediatric psoriatic arthritis and polyarticular-course juvenile idiopathic arthritis.
Tofacitinib inhibits JAK signaling involved in cytokine-mediated immune and inflammatory responses.
Yes. Tofacitinib is a Janus kinase inhibitor.
XELJANZ is the established Pfizer reference brand containing tofacitinib.
They should not be described as identical solely because both are identified as containing tofacitinib. Product-specific formulation, manufacturer and authorization information must be established.
Current U.S. XELJANZ labeling includes 5 mg and 10 mg immediate-release tablets, 11 mg and 22 mg extended-release tablets, and 1 mg/mL oral solution.
The schedule depends on the indication and formulation. Immediate-release XELJANZ is used in once- or twice-daily regimens depending on the indication, while XELJANZ XR is administered once daily.
Current U.S. XELJANZ labeling permits administration with or without food. Product-specific Tofacent instructions should be checked separately.
Common reactions include upper respiratory tract infection, nasopharyngitis, diarrhea and headache in several adult inflammatory-disease populations.
Yes. Serious bacterial, fungal, viral and opportunistic infections, including tuberculosis, are important risks.
Yes. Thrombosis, including pulmonary embolism, venous thrombosis and arterial thrombosis, is included in the boxed warning.
The U.S. boxed warning describes a higher rate of major adverse cardiovascular events compared with TNF blockers in the relevant rheumatoid arthritis safety population.
Malignancies have occurred during treatment, and the U.S. label reports higher rates of lymphoma and lung cancer compared with TNF blockers in the relevant rheumatoid arthritis population.
Current U.S. labeling recommends considering TB evaluation, viral hepatitis screening, complete blood count assessment and vaccination updates before treatment.
Yes. Increased lipid levels are a recognized laboratory effect, and lipid monitoring is part of the U.S. prescribing information.
Pregnancy considerations require professional assessment because immune-modulating therapy may involve maternal and fetal considerations. The applicable prescribing information should be consulted.
Current U.S. labeling advises against breastfeeding during XELJANZ/XELJANZ XR treatment.
The current U.S. label does not recommend combining XELJANZ/XELJANZ XR with biologic DMARDs or potent immunosuppressants such as azathioprine or cyclosporine in the listed indications.
Dose interruption or reduction can be required for certain adverse reactions, laboratory abnormalities, organ impairment or drug interactions. The applicable label should guide any modification.
Pfizer developed tofacitinib, which became associated with the reference brand XELJANZ.
The manufacturer of the specific Tofacent product is [Information requires verification].
Compare the product name, active ingredient, strength, dosage form, manufacturer, batch information and expiry information with reliable product documentation. No Tofacent-specific authentication system should be claimed without verification.